Daptomycin Compared to Vancomycin for the Treatment of Osteomyelitis: A Single-Center, Retrospective Cohort Study

Moenster, Ryan P; Linneman, Travis W; Finnegan, Patrick M.; McDonald, Jay R.

doi:10.1016/j.clinthera.2012.06.013

Cited by 24 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…, a total of 11 patients with MRSA osteoarticular infections) [13]. Another more recent study by Moenster and colleagues performed at a Veterans Affairs hospital compared daptomycin and vancomycin for osteoarticular infections but included only a subset of 23 patients with infections caused by MRSA [12]. The authors noted fewer recurrences of infection in the daptomycin group, although these findings may have limited generalizability to more heterogeneous, non-veteran populations.…”

Section: Discussionmentioning

confidence: 99%

“…Few studies have compared daptomycin vs. vancomycin for treatment of OAIs. Moenster et al published a case-control study of 51 patients with osteomyelitis but did not exclusively focus on MRSA infections; patients treated with daptomycin had significantly fewer recurrent infections six months after completing intravenous antibiotics [12]. Lalani et al performed a post hoc subanalysis of OAIs identified in a randomized controlled trial of patients with staphylococcal bloodstream infection and right-heart endocarditis, and found higher success rates in the daptomycin group [13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Daptomycin versus vancomycin for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA): a nested case–control study

Liang

Khair

McDonald

et al. 2013

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Purpose Vancomycin is the standard antibiotic for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. While daptomycin is approved for MRSA bacteremia, its effectiveness in osteoarticular infections (OAI) has not been established. Methods 1:2 nested case-control study of adult patients with MRSA OAI admitted to an academic center from 2005–2010. Clinical outcomes and drug toxicity in patients treated with daptomycin vs. vancomycin were compared. Results 20 patients with MRSA OAI treated with daptomycin were matched to 40 patients treated with vancomycin. Median age was 52 years (range, 25–90), and 40 (67%) were male. Most patients had osteomyelitis (82%), predominantly from a contiguous source (87%). Forty percent were diabetics. Diabetic patients were more likely to receive vancomycin than daptomycin [20 (50%) vs. 4 (20%); p=0.03]. Vancomycin was more often combined with other antibiotics than daptomycin [22 (55%) vs. 5 (25%); p=0.03]. Median total antibiotic treatment duration was 48 (daptomycin) vs. 46 days (vancomycin) (p=0.5). 90% of daptomycin-treated patients had previously received vancomycin for a median 14.5 days (range, 2–36). Clinical success rates were similar between daptomycin and vancomycin at 3 months [15 (75%) vs. 27 (68%); p=0.8] and 6 months [14 (70%) vs. 23 (58%); p=0.5], even after propensity score-based adjustment for antibiotic assignment. Frequency of adverse events was similar between treatment groups [1 (5%) vs. 7 (18%); p=0.2]. Conclusions Daptomycin and vancomycin achieved similar rates of clinical success and drug tolerability. Daptomycin is a reasonable alternative for treating MRSA OAIs, particularly in patients where therapy with vancomycin has not been well-tolerated.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Daptomycin versus vancomycin for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA): a nested case–control study

Liang

Khair

McDonald

et al. 2013

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

show abstract

“…Clinical effectiveness for osteomyelitis with MRSA might be non-inferior [70][71][72] , or even better than vancomycin [73] or other new agents like tigecycline, dalbavancin, linezolid and telavancin. High-dose daptomycin (up to 8 or 10 mg/kg/day) in combination with or without rifampicin was most effective in treatment of implant-associated MRSA infections [74] .…”

Section: Daptomycinmentioning

confidence: 99%

New Antibiotics in the Therapy of Osteomyelitis

Hirsiger¹,

Ilgaz²,

Uçkay³

2018

mjima

View full text Add to dashboard Cite

“…Increased prevalence of vancomycin-resistant S. aureus (VRSA), vancomycin-resistant enterococci (VRE) is already limiting its usage (Rice, 2006;Moise et al, 2009;Pawar, Bhandari, 2011;Vilhena, Bettencourt, 2012). Moenster et al (2012) states that despite adequate dosing, 30% to 50% of patients experience infection recurrence within 12 months.…”

Section: Glicopeptidesmentioning

confidence: 99%

“…The difference in pathophysiology of various types of osteomyelitis mandates specific therapeutic strategies aimed at the eradication of the infection while preserving bone integrity and function (Eid, Berbari, 2012;Moenster et al, 2012). Early antibiotic treatment, before extensive destruction of bone or necrosis, produces the best results and must be administered by the intravenous route for at least four (and usually six) weeks to achieve an acceptable rate of cure (Lew, Waldvogel, 1997).…”

Section: General Considerationsmentioning

confidence: 99%

Osteomyelitis: an overview of antimicrobial therapy

Gomes

Pereira

Bettencourt

2013

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Osteomyelitis is an inflammatory bone disorder caused by infection, leading to necrosis and destruction of bone. It can affect all ages, involve any bone, become a chronic disease and cause persistent morbidity. Treatment of osteomyelitis is challenging particularly when complex multiresistant bacterial biofilm has already been established. Bacteria in biofilm persist in a low metabolic phase, causing persistent infection due to increased resistance to antibiotics. Staphylococcus aureus and Staphylococcus epidermidis are the most common causative organism responsible for more than 50% of osteomyelitis cases. Osteomyelitis treatment implies the administration of high doses of antibiotics (AB) by means of endovenous and oral routes and should take a period of at least 6 weeks. Local drug delivery systems, using non-biodegradable (polymethylmethacrylate) or biodegradable and osteoactive materials such as calcium orthophosphates bone cements, have been shown to be promising alternatives for the treatment of osteomyelitis. These systems allow the local delivery of AB in situ with bactericidal concentrations for long periods of time and without the toxicity associated with other means of administration. This review examines the most recent literature evidence on the causes, pathogeneses and pharmacological treatment of osteomyelitis. A osteomielite é um processo inflamatório do tecido ósseo, de origem infecciosa, que resulta em destruição inflamatória, necrose e formação de novo osso. Pode aparecer em qualquer idade, afetar qualquer osso e tornar-se uma doença crônica com morbidade persistente. Apesar dos progressos na quimioterapia infecciosa, o tratamento da osteomielite é caro e difícil, em particular quando associada à presença de biofilmes bacterianos, especialmente de Staphylococcus aureus e Staphylococcus epidermidis. O tratamento da osteomielite inclui a administração de doses elevadas de antibióticos (AB) por via endovenosa e oral, durante um período de pelo menos 6 semanas. Os sistemas de veiculação localizada de fármacos, utilizando materiais não biodegradáveis (polimetilmetacrilato) ou biodegradáveis e osteoativos como os cimentos ósseos de ortofosfatos de cálcio e vidro bioativo, surgiram como uma alternativa promissora para o tratamento da osteomielite. Estes sistemas permitem a veiculação de AB in situ com concentrações bactericidas por longos períodos de tempo e sem a toxicidade associada às outras vias de administração. O presente trabalho propõe uma revisão da literatura relativa às causas, à patogenia e ao tratamento farmacológico da osteomielite. A metodologia do estudo da revisão consistiu numa pesquisa bibliográfica, nas bases de dados Google Scholar, Science Direct, Pubmed, Springer link, B-on. Foram revistos e analisados diversos artigos publicados desde o ano de 1979.Unitermos: Osteomielite/tratamento farmacológico. Osteomielite/terapia antimicrobial. Staphylococcus aureus/presença/osteomielite. Antibióticos/uso/tratamento da osteomielite.

show abstract

Daptomycin Compared to Vancomycin for the Treatment of Osteomyelitis: A Single-Center, Retrospective Cohort Study

Cited by 24 publications

References 16 publications

Daptomycin versus vancomycin for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA): a nested case–control study

Daptomycin versus vancomycin for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA): a nested case–control study

New Antibiotics in the Therapy of Osteomyelitis

Osteomyelitis: an overview of antimicrobial therapy

Contact Info

Product

Resources

About